Anti-PEM monoclonal antibody

Drug Profile

Anti-PEM monoclonal antibody

Alternative Names: huBrE-3 mAb; Phoenix

Latest Information Update: 22 Nov 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Immunodex
  • Developer Somanta Pharmaceuticals
  • Class Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Breast cancer

Most Recent Events

  • 16 Feb 2006 Somanta has changed its name to Somanta Pharmaceuticals
  • 01 Jun 2005 Phase-I/II clinical trials in Cancer in USA (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top